
    
      In this study Influenza vaccine GSK1562902A is the primary study vaccine and Havrix™ will be
      administered as the active comparator and not co-administered along with the study
      vaccine.Therefore, there exist no relation between the vaccines administered in this study.
      As the study will be carried out in Philippines, Havrix™ vaccine will be used as an active
      comparator instead of saline placebo to offer an advantage to the subjects.
    
  